These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 2576255

  • 21. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 22. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D.
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [Abstract] [Full Text] [Related]

  • 23. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M, Røde A, Westergaard J.
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [Abstract] [Full Text] [Related]

  • 24. Oral contraception with a triphasic combination of gestodene and ethinyl estradiol: results of a multicenter clinical study.
    Skouby SO.
    Int J Fertil; 1987 Sep; 32 Suppl():45-8. PubMed ID: 2906346
    [Abstract] [Full Text] [Related]

  • 25. [Clinical study of two monophase oral contraceptives with desogestrel].
    Uchikova E, Milchev N, Markova D, Batashki I, Gŭrova A.
    Akush Ginekol (Sofiia); 2007 Sep; 46(2):18-21. PubMed ID: 17469446
    [Abstract] [Full Text] [Related]

  • 26. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
    Zichella L, Sbrignadello C, Tomassini A, Di Lieto A, Montoneri C, Zarbo G, Mancone M, Pietrobattista P, Bertoli G, Perrone G.
    Adv Contracept; 1999 Sep; 15(3):191-200. PubMed ID: 11019950
    [Abstract] [Full Text] [Related]

  • 27. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM, Thomas CM, Borm GF, Rolland R.
    Int J Fertil Menopausal Stud; 1995 Sep; 40 Suppl 2():92-7. PubMed ID: 8574256
    [Abstract] [Full Text] [Related]

  • 28. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N.
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [Abstract] [Full Text] [Related]

  • 29. A new ultra-low-dose combination oral contraceptive.
    Woutersz TB.
    J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene.
    Renier M, Buytaert P.
    Contraception; 1991 May; 43(5):413-21. PubMed ID: 1914456
    [Abstract] [Full Text] [Related]

  • 32. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
    Affinito P, Monterubbianesi M, Primizia M, Regine V, Di Carlo C, Farace MJ, Petrillo G, Nappi C.
    Gynecol Endocrinol; 1993 Dec; 7(4):259-66. PubMed ID: 8147235
    [Abstract] [Full Text] [Related]

  • 33. Long-term experience with a low-dose oral contraceptive.
    Brill K, Schnitker J, Albring M.
    Gynecol Endocrinol; 1990 Dec; 4(4):277-86. PubMed ID: 2150581
    [Abstract] [Full Text] [Related]

  • 34. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC, Filho CI, Faggion D, Baracat EC.
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [Abstract] [Full Text] [Related]

  • 35. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M.
    Acta Obstet Gynecol Scand Suppl; 1997 Jan; 164():63-5. PubMed ID: 9225641
    [Abstract] [Full Text] [Related]

  • 36. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R.
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
    Halbe HW, de Melo NR, Bahamondes L, Petracco A, Lemgruber M, de Andrade RP, da Cunha DC, Guazelli CA, Baracat EC.
    Eur J Contracept Reprod Health Care; 1998 Sep; 3(3):113-20. PubMed ID: 9853201
    [Abstract] [Full Text] [Related]

  • 38. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J, Daume E, Simon A, Winkler UH, Schindler AE, Back DJ, Ward S, Neiss A.
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Clinical experience with Mercilon and Marvelon with special reference to ovarian function].
    Mall-Haefeli M, Werner-Zodrow I, Huber PR.
    Geburtshilfe Frauenheilkd; 1991 Jan; 51(1):34-8. PubMed ID: 1827418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.